Neoleukin Therapeutics Statistics Share Statistics Neoleukin Therapeutics has 2.35M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 2.35M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 1.36M Failed to Deliver (FTD) Shares 1,000 FTD / Avg. Volume 18.12%
Short Selling Information The latest short interest is 34.66K, so 0% of the outstanding
shares have been sold short.
Short Interest 34.66K Short % of Shares Out n/a Short % of Float 0.1% Short Ratio (days to cover) 1.12
Valuation Ratios The PE ratio is -0.88 and the forward
PE ratio is null.
Neoleukin Therapeutics's PEG ratio is
0.
PE Ratio -0.88 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.21 P/FCF Ratio -0.93 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Neoleukin Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 20.84,
with a Debt / Equity ratio of 0.04.
Current Ratio 20.84 Quick Ratio 20.84 Debt / Equity 0.04 Debt / EBITDA -0.15 Debt / FCF -0.17 Interest Coverage 6883.75
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-10.73M Employee Count 7 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.1, so Neoleukin Therapeutics's
price volatility has been higher than the market average.
Beta 1.1 52-Week Price Change n/a 50-Day Moving Average 3.46 200-Day Moving Average 3.73 Relative Strength Index (RSI) 51.69 Average Volume (20 Days) 5,520
Income Statement
Revenue n/a Gross Profit n/a Operating Income -82.61M Net Income -75.14M EBITDA -82.61M EBIT n/a Earnings Per Share (EPS) -3.96
Full Income Statement Balance Sheet The company has 136.59M in cash and 12.43M in
debt, giving a net cash position of 124.16M.
Cash & Cash Equivalents 136.59M Total Debt 12.43M Net Cash 124.16M Retained Earnings -262.3M Total Assets 315.3M Working Capital 282.3M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -70.6M
and capital expenditures -808K, giving a free cash flow of -71.41M.
Operating Cash Flow -70.6M Capital Expenditures -808K Free Cash Flow -71.41M FCF Per Share -3.76
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields NLTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for NLTX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 19, 2023. It was a
backward
split with a ratio of 1:4.
Last Split Date Dec 19, 2023 Split Type backward Split Ratio 1:4
Scores Altman Z-Score -1.24 Piotroski F-Score 3
